Media Center
Publications
Preclinical and clinical development of ABTL0812: a new antitumoral drug that induces autophagy-mediated cancer cell death by upregulating TRIB3 pseudokinase and impairing of Akt/mTORC1 axis.
1st Oncobell Symposium. Mechanisms of Cancer and New Therapeutic Strategies. Barcelona 2018.
P. Muñoz-Guardiola, E. Megías-Roda, T. Erazo, H. Pérez, S. Solé-Sánchez, N. Diéguez, M. Yeste, M. Cortal, G. Velasco, J. Alfon, C. Domènech, J.M. Lizcano.
Exploring pharmacokinetic/pharmacodynamic considerations in translational oncology; from preclinical development to Phase II operations
Outsourcing in Clinical Trials. Barcelona 2018.
Jose Alfón
Preclinical and clinical development of ABTL0812: a new antitumoral drug that induces autophagy-mediated cancer cell death by upregulating TRIB3 pseudokinase and impairing of Akt/mTORC1 axis.
16th International Congress ASEICA, 2018.
P. Muñoz-Guardiola, T. Erazo, E. Megías-Roda, H. Pérez-Montoyo, S. Solé-Sánchez, N. Diéguez-Martínez, M. Yeste, M. Cortal, L. Vidal, P. Gascon, M. Gil, M. Romeo, T. Moran, G. Velasco, Jose Alfón, C. Domènech, J.M. Lizcano.
Development of TRIB3 as a novel preclinical and clinical pharmacodynamic biomarker for ABTL0812
J Clin Oncol 36, 2018 (suppl; abstr e14556).
H. Pérez-Montoyo, M. Yeste-Velasco, S. Solé-Sánchez, P. Bragado, E. Colàs-Ortega, N. Eritja, A. Lopez-Plana, P. Fernandez-Nogueira, P. Muñoz-Guardiola, E. Megías-Roda, C. Moiola, I. Felip, E. Nadal-Alforja, M. Gil Martin, M. Romeo, T. Moran, A. Gil-Moreno, X. Matias-Guiu, C. Domenech, J.M. Lizcano
The new antitumoral drug ABTL0812 induces autophagic cell death by a dual mechanism: inhibition of Akt/mTORC1 axis and impairing desaturase-1 activity.
Transautophagy, Copenhaguen 2017.
Pau Muñoz-Guardiola, Josefina Casas , Elisabet Megías, Nora Diéguez, Mar Lorente, Pedro Rayo, Tatiana Erazo, Sònia Solé-Sánchez, José Alfón, Carles Domènech, Héctor Pérez, Guillermo Velasco, Gemma Fabriàs, Jose M. Lizcano.
Determination of recommended phase II dose of ABTL0812, a novel regulator of Akt/mTOR axis, by pharmacokinetic-pharmacodynamic modelling
Published: 11 Oct. 2016
Ann Oncol (2016) 27 (suppl_6): 378P
J. Alfon L. Vidal L. Gaba I. Victoria M. Gil B. Laquente M. Brunet H. Colom J. Ramis H. Perez-Montoyo M. Cortal M. Gomez-Ferreria P. Muñoz T. Erazo J.M. Lizcano C. Domenech P. Gascon
The New Antitumor Drug ABTL0812 Inhibits the Akt/mTORC1 Axis by Upregulating Tribbles-3 Pseudokinase
Published: 15 May 2016 10.1158/1078-0432.CCR-15-1808
Tatiana Erazo, Mar Lorente, Anna López-Plana, Pau Muñoz-Guardiola, Patricia Fernández-Nogueira, José A. García-Martínez, Paloma Bragado, Gemma Fuster, María Salazar, Jordi Espadaler, Javier Hernández-Losa, Jose Ramon Bayascas, Marc Cortal, Laura Vidal, Pedro Gascón, Mariana Gómez-Ferreria, José Alfón, Guillermo Velasco, Carles Domènech and Jose M. Lizcano
LATEST NEWS
04.02.2019
News
Ability Pharmaceuticals Announces the Approval in China of a Clinical Study in Pancreatic Cancer with ABTL0812 + info
30.01.2019
News
Ability Pharmaceuticals is attending the BIOMED EVENT® by INVEST SECURITIES and the Cholangiocarcinoma Foundation Annual Conference + info
05.12.2018
News
AbilityPharma ha superado el millón de euros en la ronda de crowdfunding que abrió el pasado mes de septiembre + info
07.11.2018
News
Ability Pharmaceuticals Announces FDA-Orphan Drug Designation for ABTL0812 in Biliary Tract Cancer + info
19.09.2018
News
Ability Pharmaceuticals anuncia la inclusión del primer paciente en el estudio clínico de la fase 2 de ABTL0812 en Francia + info
24.08.2018
News
At AbilityPharma we are very pleased to announce the start of a crowdfunding campaign through de Capital Cell + info
19.02.2018
News
AbilityPharma Announces FDA Approval of Phase 1/2 Trial of ABTL0812 for Patients with Advanced Metastatic Pancreatic Cancer + info
13.12.2017
News
AbilityPharma Announces FDA Approval of IND for Phase 2 Trial of ABTL0812 in Patients with Endometrial Cancer or Squamous Non-Small Cell Lung Cancer + info
05.10.2017
News
Ability Pharmaceuticals announces the approval from the French Medicines Agency ANSM to initiate a Phase 1/2a Clinical Trial with ABTL0812 to treat patients with endometrial cancer or squamous lung cancer as first-line therapy in France + info
